Topic Archives: Merck (MRK)

“Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

Oncotutorial

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Skousen’s “must have” cancer killer stock… and it’s “one of the world’s oldest, publicly traded companies”

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough. Not this time, apparently. So that’s why my eye was […]

Like A Bell You Can’t Unring

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. You can see his biography, previous columns and most recent comments on his Stock Gumshoe page.] “We ran the race,  the race […]

The Manchurian Candida

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

The Tao of Recro

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles here.] “Who wants honey? As long as there’s some money?” —–“Cherub Rock,” Smashing Pumpkins, Siamese Dream (words and […]

Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Just For the Record

[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who is sharing his experiences as a financial advisor with us. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas. His previous articles can be seen here.]  Hello, fellow […]

Comments

  • Avatar

    Good work! Elfenbein appears to have missed the first cycle move on CTST, but might be close on the entry for the next o...

  • Avatar

    Merck (MRK) Keytruda/Chemo combo getting a lot of attention at ESMO. https://endpts.com/esmo-roundup-immune-design-roll...

  • Avatar

    $MRK - breaking Merck snaps up a German immuno-oncology upstart in a $603M bolt-on deal Munich-based Rigontec is d...

  • Avatar

    $ESPR (of high relevance) $MRK $CETP Merck hits a bloop single in an epic PhIII CETP cardio contest. Now what? (Endpo...

  • Avatar

    $ESPR $MRK #CETP #CVOT Merck Provides Update on REVEAL Outcomes Study of Anacetrapib Business Wire Business WireJu...

  • Avatar

    Should bode well for $NTRP Long $NTRP Merck $MRK announced late Tuesday that it is shuttering its EPOCH trial for ...

  • Avatar

    Dear KSS. Since Merck ($MRK) settled with Bristol Meyer ($BMY) Friday regarding anti-PD-1 antibodies has this set a prec...

  • Avatar

    $INCY $MRK: Shares of Incyte ($INCY) soared Monday on the heels of news that the company and Merck ($MRK) will condu...

  • Avatar

    Merck (MRK) with good news. http://www.marketwatch.com/story/merck-beats-profit-expectations-bumps-up-full-year-guida...

  • Avatar

    I will also clarify that the Merck/ECYT deal was with Merck (MRK), not Merck KGaA (EMD Serono) so they were different co...

  • Avatar

    $ESPR Red Acre Investments · @redacre http://www.twitlonger.com/show/n_1snl7e3 13th Oct 2015 from TwitLonger Thesis...

  • Dr. KSS, MD PhD

    Although I have never understood why Merck $MRK received it, the FDA has yanked Breakthrough Therapy Designation for its...

  • Avatar

    RE:GILD – good news from Barron’s. Long GILD. RBC’s Michael Yee and team think AbbVie’s (ABBV) update on its he...

  • Travis Johnson, Stock Gumshoe

    True, there are always expensive companies, but that's 20X estimated earnings for 2017, 30 months into the future. BMY ...

  • Avatar

    Just saw this - another entry in the HCV parade: Jackpot for Idenix Shareholders -- Market TalkMonday 06/09/2014 07:41 ...

  • Avatar

    om and others. Here is the WSJ article. Sorry for the delay. It was sunny in Seattle and you gotta take advantage ...

  • om sharma

    Companies those working on RNA therapeutics, like Fierce Biotech broke the news that the Swiss giant, Novartis (NVS) was...

  • Avatar

    In regards to OPK; Opko Health (OPK), is expecting to announce top-line results from its Phase III trial for rola...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch